Skip to main content
Home
  • About
    • About SGC
    • Member Funders
    • Governance
    • Open Science
    • Impact
  • SGC Sites & People
    • Global
    • SGC Toronto
    • SGC UNC
    • SGC Karolinska
    • SGC Frankfurt
    • SGC Neuro
    • SGC UCL
    • SGC Unicamp
  • Science and Resources
    • Proteins
      • Structure Gallery
      • Protein Production Resources
        • Expression Vectors
        • Constructs
    • Chemistry
      • Chemical Probes
        • SGC Chemical Probes
        • Donated Chemical Probes
        • Chemical Handles
      • Chemogenomic Sets
    • Open Data
    • Target Enabling Packages
    • Patient Tissue Platform
    • Open Lab Notebooks
    • Publications
    • Bioinformatics Resources
      • ChemBioPort
      • UbiHub
      • ChromoHub
  • Initiatives
    • Overview
      • Open Chemistry Networks
      • Target 2035
      • CACHE
      • Women’s and Children’s Health Initiative
      • Conscience
      • READDI AViDD
      • Agora Open Science Trust
      • TREAT AD
      • EUbOPEN
      • YCharOS
      • Contribute your Proteins to Target 2035
  • News & Outreach
    • News from SGC
    • Press Releases
    • Blogs
  • Get Involved
    • Participate
    • Donate
    • Careers
    • Contact Us
  • Home
  • About
    • About SGC
    • Member Funders
    • Governance
    • Open Science
    • Impact
  • SGC Sites & People
    • Global
    • SGC Toronto
    • SGC UNC
    • SGC Karolinska
    • SGC Frankfurt
    • SGC Neuro
    • SGC UCL
  • Science and Resources
    • Proteins
      • Structure Gallery
      • Protein Production Resources
        • Expression Vectors
        • Constructs
    • Chemistry
      • Chemical Probes
        • SGC Chemical Probes
        • Donated Chemical Probes
        • Chemical Handles
      • Chemogenomic Sets
        • EUbOPEN Chemogenomic Sets
        • KCGS
    • Open Data
    • Target Enabling Packages
    • Patient Tissue Platform
    • Open Lab Notebooks
    • Publications
    • Bioinformatics Resources
      • ChemBioPort
      • UbiHub
      • ChromoHub
  • Initiatives
    • Overview
      • Open Chemistry Networks
      • Target 2035
      • CACHE
      • Women’s and Children’s Health Initiative
      • Viral Medicines Initiative
      • READDI AViDD
      • Agora Open Science Trust
      • TREAT AD
      • EUbOPEN
      • YCharOS
  • News & Outreach
    • News from SGC
    • Press Releases
    • Blogs
  • Get Involved
    • Participate
    • Donate
    • Careers
    • Contact Us

SS148 and WZ16 inhibit the activities of nsp10-nsp16 complexes from all seven human pathogenic coronaviruses.

  • Read more about SS148 and WZ16 inhibit the activities of nsp10-nsp16 complexes from all seven human pathogenic coronaviruses.

Toward effective Atg8-based ATTECs: Approaches and perspectives.

  • Read more about Toward effective Atg8-based ATTECs: Approaches and perspectives.

Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.

  • Read more about Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21.

Histone H4K20 monomethylation enables recombinant nucleosome methylation by PRMT1 in vitro.

  • Read more about Histone H4K20 monomethylation enables recombinant nucleosome methylation by PRMT1 in vitro.

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors.

  • Read more about Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors.

RAS and PP2A activities converge on epigenetic gene regulation.

  • Read more about RAS and PP2A activities converge on epigenetic gene regulation.

Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators.

  • Read more about Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators.

Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.

  • Read more about Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.

Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.

  • Read more about Oxazolo[5,4-f]quinoxaline-type selective inhibitors of glycogen synthase kinase-3α (GSK-3α): Development and impact on temozolomide treatment of glioblastoma cells.

Reference compounds for characterizing cellular injury in high-content cellular morphology assays.

  • Read more about Reference compounds for characterizing cellular injury in high-content cellular morphology assays.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 177
  • Page 178
  • Page 179
  • Page 180
  • Current page 181
  • Page 182
  • Page 183
  • Page 184
  • Page 185
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

A global public-private partnership that supports the discovery of new medicines through open-access research.

  • Careers
  • Contact Us

Structural Genomics Consortium. Registered charity 04714553 (England and Wales). Registered company limited by guarantee 1097737 (England and Wales). Except where otherwise noted, all content on this site is licensed under a Creative Commons Attribution 4.0 International license (CC BY 4.0)

Be the first to know with our SGC Bulletin!

Want to know what we are up to?
Leave your e-mail address below and you will receive a monthly source of SGC news from across our six research sites.

SIGN UP FOR OUR NEWSLETTER

Footer

  • Privacy Policy
  • Legal Information
  • Accessbility
  • Contact Us
  • Login

Toronto website development by Rebel Trail